Search
Dextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnThe drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. … Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions.
Pegaptanib
go.drugbank.com/drugs/DB04895ApprovedWithdrawnPegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.
Tazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.
Mixtures: AVITAZ 2.25 G I.V. ENJEKSIYONLUK LIYOFILIZE TOZ IÇEREN FLAKON ,FLAKON, 1 ADET, AVITAZ 4.5 G I.V. ENJEKSIYONLUK LIYOFILIZE TOZ IÇEREN FLAKON ,FLAKON, 1 ADETAndexanet alfa
go.drugbank.com/drugs/DB14562ApprovedAndexanet alfa retains the structural similarity to that of endogenous human factor Xa, but exists in its mature functional form without the need for activation via the intrinsic or extrinsic coagulation … It also prevents andexanet alfa from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex [A35558].
Cetuximab
go.drugbank.com/drugs/DB00002ApprovedInvestigational[A227963] Approved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic
Crovalimab
go.drugbank.com/drugs/DB16128ApprovedInvestigational[L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
NKG2D-ACE2 CAR-NK Cell
go.drugbank.com/drugs/DB15727InvestigationalThe transmembrane NKG2D and intracellular 2B4 domains are required for optimal NK signalling and subsequent cell-mediated cytotoxicity. … These cells are prepared as universal off-the-shelf CAR-NK cells from cord blood with NKG2D-ACE2 proteins engineered as part of the CARs; the cell secretes IL-15 and GM-CSF.
Synonyms: ACE2 CAR-NK Cell, NKG2D CAR-NK CellCarbidopa
go.drugbank.com/drugs/DB00190ApprovedInvestigational[L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination … therapy developed by Mayne Pharma in 1992.
Olanzapine
go.drugbank.com/drugs/DB00334ApprovedInvestigational[A177011] Olanzapine was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.[T548]
Fingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalIt was developed by Novartis and initially approved by the FDA in 2010.[L12651] Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.